TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure

Lei, J; Chen, BW; Song, MR; Zhang, LZ; Zhang, XF; Gao, XQ; Li, YY; Lu, YY; Zuo, S

Lu, YY; Zuo, S (通讯作者)，Guizhou Med Univ, Guiyang, Peoples R China.;Lu, YY (通讯作者)，Peoples Liberat Army Gen Hosp, Comprehens Liver Canc Ctr, Med Ctr 5, Beijing, Peoples R China.;Zuo, S (通讯作者)，Guizhou Med Univ, Affiliated Hosp, Dept Hepatobiliary Surg, Guiyang, Peoples R China.;Lu, YY (通讯作者)，Shenzhen Univ, Coll Life Sci & Oceanog, Guangdong Key Lab Epigenet, Shenzhen, Peoples R China.

FRONTIERS IN PHARMACOLOGY, 2022; 13 ():

Abstract

Background: Tyrosine kinase inhibitors (TKI) in combination with programmed cell death-1 (PD-1) inhibitors become the potential treatment modality for......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索